mds-news - HealthTree for Myelodysplastic Syndromes

New in MDS

Here you will find articles that discuss the latest advances in MDS. You will be kept up to date on the newest FDA drug approvals for MDS drugs and treatment combinations. You will also learn about newly published research studies and any advances or findings that may contribute to your MDS treatment. We will discuss topics such as newly discovered MDS genetic mutations, exciting advances on new therapies like CAR-T therapy and NK cells, and improvements in allogeneic stem cell transplant.

Articles posted here will also aim to help answer common questions like "how is MDS treated?", "how is MDS diagnosed?", and "what causes MDS?".

With new MDS research being published almost every day, there is a lot to keep track of. The articles in this category will help you stay informed of new MDS treatment options and MDS research findings which will ultimately make you an empowered patient. Being empowered allows you to take important information to your healthcare team for discussion that will further enhance and personalize your care.

Managing Iron Overload In MDS

November 09, 2023

mds 101, life with mds, iron overload and mds, iron chelation therapy

A New Treatment Option Being Investigated For High Risk MDS And AML Patients

November 09, 2023

mds, aml, Bemcentinib, new in mds, life with mds, new treatment for HR-MDS

Ivosidenib Approved For Treating Relapse Or Refractory MDS With An IDH1 Mutation

October 24, 2023

Ivosidenib and MDS. IDH1 mutation, relapsed or refractory MDS, Life with MDS, New in MDS

The Promising Treatment Of Imetelstat And Transfusion Independence

October 05, 2023

Imetelstat and low risk mds, life with mds, mds clinical trial, imetelstat and transfusions, transfusion independence

The Use Of Antithymocyte Globulin Immunotherapy When Treating Low-Risk MDS

October 03, 2023

Immunosuppressive therapy can be an option for patients with lower-risk MDS (LR-MDS). A common type of immunotherapy for MDS is antithymocyte globulin (ATG).